Cingulate Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 23.53 million compared to USD 17.68 million a year ago. Basic loss per share from continuing operations was USD 26 compared to USD 29.35 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.825 USD | +2.47% | +4.43% | -89.22% |
05-21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
05-08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-89.22% | 4.99M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.38% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- CING Stock
- News Cingulate Inc.
- Cingulate Inc. Reports Earnings Results for the Full Year Ended December 31, 2023